دورية أكاديمية
أعرض في EDS

Immune mechanisms and predictive biomarkers related to neoadjuvant immunotherapy response in stage III melanoma.

التفاصيل البيبلوغرافية
العنوان: Immune mechanisms and predictive biomarkers related to neoadjuvant immunotherapy response in stage III melanoma.
المؤلفون: Figueiredo AB; Translational Immuno-Oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.; Translational Immuno-Oncology Laboratory, Education and Research Center, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.; Center for Research in Immuno-Oncology (CRIO), Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Barros E Silva MJ; Clinical Oncology Department, AC Camargo Cancer Center, São Paulo, Brazil., Evangelista GFB; Translational Immuno-Oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Galdino NAL; Translational Immuno-Oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Kuil LM; Translational Immuno-Oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Santos IP; Translational Immuno-Oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Morais KLP; Translational Immuno-Oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Cavalcanti CM; Translational Immuno-Oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil., Moredo LF; Cutaneous Oncology Department, AC Camargo Cancer Center, São Paulo, Brazil., Duprat-Neto JP; Cutaneous Oncology Department, AC Camargo Cancer Center, São Paulo, Brazil., Gollob KJ; Translational Immuno-Oncology Group, International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.; Translational Immuno-Oncology Laboratory, Education and Research Center, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.; Center for Research in Immuno-Oncology (CRIO), Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
المصدر: Heliyon [Heliyon] 2024 Jun 11; Vol. 10 (12), pp. e32624. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : Elsevier Ltd, [2015]-
مستخلص: The treatment for stage III melanoma has advanced significantly, nevertheless, a substantial proportion of patients experience relapse. Neoadjuvant immune checkpoint blockade has emerged as a promising approach, allowing early micrometastatic disease treatment, reduction of tumor burden before surgery, and enhanced tumor-specific T-cell responses. However, not all patients respond to treatment, highlighting the need for understanding immune mechanisms behind failure and identification of predictive markers. Here we performed a robust evaluation of systemic and tumoral immune profiles in a well-defined cohort of advanced melanoma patients treated with immune checkpoint inhibitors. Elevated CTACK and CXCL9 chemokines pre-treatment suggested their potential as predictive tools for treatment response. Furthermore, CD95 expression in CD8 + T lymphocytes surfaced as a favorable prognostic indicator, while PD-1, CD161, and PD-L2 exhibited correlations with worst outcomes. These findings shed light on the intricate interplay between immune markers and melanoma response to neoadjuvant immune checkpoint therapy, offering insights into personalized treatment strategies.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kenneth Gollob reports financial support, administrative support, article publishing charges, and equipment, drugs, or supplies were provided by GSK via the academic grant between FAPESP and GSK. Other authors, declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2024 The Authors.)
References: Cancer Sci. 2022 Feb;113(2):756-769. (PMID: 34881489)
J Immunother Cancer. 2021 Sep;9(9):. (PMID: 34593622)
Sci Rep. 2022 Mar 31;12(1):5448. (PMID: 35361879)
Drugs. 2017 Aug;77(12):1313-1336. (PMID: 28616845)
Cell Death Differ. 2011 Apr;18(4):619-31. (PMID: 21052094)
N Engl J Med. 2018 May 10;378(19):1789-1801. (PMID: 29658430)
Immunity. 2019 Jun 18;50(6):1498-1512.e5. (PMID: 31097342)
Cell Rep. 2017 May 9;19(6):1189-1201. (PMID: 28494868)
J Clin Pathol. 2017 Jan;70(1):15-19. (PMID: 27325798)
Oncoimmunology. 2016 Sep 20;5(11):e1235107. (PMID: 27999753)
Nat Med. 2018 Nov;24(11):1655-1661. (PMID: 30297911)
J Exp Med. 2009 Jun 8;206(6):1379-93. (PMID: 19487421)
N Engl J Med. 2017 Nov 9;377(19):1824-1835. (PMID: 28891423)
Lancet Oncol. 2019 Jul;20(7):e378-e389. (PMID: 31267972)
N Engl J Med. 2017 Nov 9;377(19):1813-1823. (PMID: 28891408)
Front Pharmacol. 2017 Aug 23;8:561. (PMID: 28878676)
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70. (PMID: 25969447)
PLoS One. 2018 Jun 6;13(6):e0196464. (PMID: 29874226)
Nat Med. 2021 Feb;27(2):301-309. (PMID: 33558722)
Lancet Oncol. 2019 Jul;20(7):948-960. (PMID: 31160251)
Nat Med. 2018 Nov;24(11):1649-1654. (PMID: 30297909)
Cell. 2023 Apr 13;186(8):1652-1669. (PMID: 37059068)
Clin Cancer Res. 2020 Jan 15;26(2):487-504. (PMID: 31636098)
Cell. 2021 Mar 4;184(5):1281-1298.e26. (PMID: 33592174)
Cancer Cell. 2020 Nov 9;38(5):685-700.e8. (PMID: 33007259)
J Immunother Cancer. 2018 Jan 25;6(1):4. (PMID: 29368638)
فهرسة مساهمة: Keywords: Biomarkers; Immunomodulation; Immunotherapy; Melanoma; Neoadjuvant therapy
تواريخ الأحداث: Date Created: 20240708 Latest Revision: 20240709
رمز التحديث: 20240709
مُعرف محوري في PubMed: PMC11226767
DOI: 10.1016/j.heliyon.2024.e32624
PMID: 38975149
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-8440
DOI:10.1016/j.heliyon.2024.e32624